Sugi Predict

Sugi Predict / Compounds / Mirisetron

Mirisetron

Mirisetron

SCHEMBL194840

CN1[C@@H]2CC[C@H]1C[C@@H](NC(=O)c1cn(C3CCCCC3)c3ccccc3c1=O)C2

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.61
▸ MEN1 O00255 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ HTR3A P46098 10/20 0.59
▸ HTR3E A5X5Y0 7/20 0.59
▸ HTR3B O95264 7/20 0.59
▸ HTR3D Q70Z44 7/20 0.59
▸ HTR3C Q8WXA8 7/20 0.59
▸ SLC22A2 O15244 1/20 0.54
▸ CHRNB2 P17787 1/20 0.54
▸ CHRNA3 P32297 1/20 0.54
▸ CHRNA4 P43681 1/20 0.54
▸ KCNH2 Q12809 1/20 0.54
▸ SLC47A1 Q96FL8 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ CNR1 P21554 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mirisetron SCHEMBL6695569 1.00 KDM4E (0.61) KDM4EMEN1KMT2AHTR3AHTR3E
Mirisetron SCHEMBL194841 1.00 KDM4E (0.61) KDM4EMEN1KMT2AHTR3AHTR3E
SCHEMBL9029352 0.96 HTR3A (0.63) KDM4EMEN1KMT2AHTR3AHTR3E
Mirisetron SCHEMBL121861 0.94 KDM4E (0.58) KDM4EMEN1KMT2AHTR3AHTR3E
Mirisetron SCHEMBL121862 0.94 KDM4E (0.58) KDM4EMEN1KMT2AHTR3AHTR3E
Mirisetron SCHEMBL7362107 0.94 KDM4E (0.58) KDM4EMEN1KMT2AHTR3AHTR3E
Mirisetron SCHEMBL678308 0.94 KDM4E (0.58) KDM4EMEN1KMT2AHTR3AHTR3E
SCHEMBL9028258 0.86 HTR3A (0.60) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL9027434 0.86 HTR3A (0.64) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL16378030 0.83 CNR1 (0.57) HTR3AHTR3EHTR3BHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016118540-A1 TREATING AND/OR PREVENTING EMESIS AND/OR NAUSEA INCLUDING ACUTE AND/OR DELAYED NAUSEA AND/OR EMESIS Xoc Pharmaceuticals, Inc. (US) 2016-07-28 — — WO claimed
US-20160206610-A1 METHODS FOR TREATING AND/OR PREVENTING EMESIS AND/OR NAUSEA INCLUDING ACUTE AND/OR DELAYED NAUSEA AND/OR ACUTE EMESIS AND/OR DELAYED EMESIS Xoc Pharmaceuticals, Inc. 2016-07-21 — — US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
WO-2011126937-A1 TARGETED INTRACELLULAR DELIVERY OF OLIGONUCLEOTIDES VIA CONJUGATION WITH SMALL MOLECULE LIGANDS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2011-10-13 — — WO claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 — — EP claimed
WO-2002036113-A1 COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) RESPIRATORIUS AB (SE) 2002-05-10 — — WO claimed
WO-2002036114-A1 COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 RESPIRATORIUS AB (SE) 2002-05-10 — — WO claimed
WO-2001095902-A9 A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS — 2002-04-25 — — WO claimed
WO-2001095902-A1 A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS RESPIRATORIUS AB (SE) 2001-12-20 — — WO claimed
WO-2001095903-A1 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION RESPIRATORIUS AB (SE) 2001-12-20 — — WO claimed
WO-1997041878-A1 TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE MERCK & CO., INC. (US) 1997-11-13 — — WO claimed
US-20250152742-A1 COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES TRAMES BIO, INC. 2025-05-15 — — US disclosed
US-20240397918-A1 NON-MEIOTIC ALLELE INTROGRESSION RECOMBINETICS, INC. 2024-12-05 — — US disclosed
WO-1997041878-A1 TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE MERCK & CO., INC. (US) 1997-11-13 — — WO disclosed
WO-1997010823-A1 5-HT3 RECEPTOR ANTAGONISTS FOR DYSKINESIA GLAXO GROUP LIMITED (GB) 1997-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250152742-A1 COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES CHRNB2, CHRNA2, CHRNA6 KDM4E 4711/4885MEN1 2410/4885KMT2A 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.